Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free ACB Stock Alerts

Aurora Cannabis (ACB) Competitors

Aurora Cannabis logo
C$4.21 -0.38 (-8.28%)
As of 12:06 PM Eastern
Compare

ACB vs. DHT.UN, THCX, TLRY, GUD, and WEED

Should you buy Aurora Cannabis stock or one of its competitors? MarketBeat compares Aurora Cannabis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aurora Cannabis include DRI Healthcare Trust (DHT.UN), Hydropothecary (THCX), Tilray Brands (TLRY), Knight Therapeutics (GUD), and Canopy Growth (WEED). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does Aurora Cannabis compare to DRI Healthcare Trust?

Aurora Cannabis (TSE:ACB) and DRI Healthcare Trust (TSE:DHT.UN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

DRI Healthcare Trust has lower revenue, but higher earnings than Aurora Cannabis. DRI Healthcare Trust is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora CannabisC$373.12M0.67-C$44.16M-C$1.50N/A
DRI Healthcare TrustC$163.77M6.12C$9.73M-C$0.90N/A

In the previous week, Aurora Cannabis had 1 more articles in the media than DRI Healthcare Trust. MarketBeat recorded 2 mentions for Aurora Cannabis and 1 mentions for DRI Healthcare Trust. DRI Healthcare Trust's average media sentiment score of 1.13 beat Aurora Cannabis' score of 0.00 indicating that DRI Healthcare Trust is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aurora Cannabis
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
DRI Healthcare Trust
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

4.6% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 0.6% of DRI Healthcare Trust shares are owned by institutional investors. 0.1% of DRI Healthcare Trust shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Aurora Cannabis presently has a consensus target price of C$9.25, indicating a potential upside of 119.71%. DRI Healthcare Trust has a consensus target price of C$25.50, indicating a potential upside of 39.96%. Given Aurora Cannabis' higher possible upside, analysts clearly believe Aurora Cannabis is more favorable than DRI Healthcare Trust.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurora Cannabis
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
DRI Healthcare Trust
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Aurora Cannabis has a beta of 0.174133, indicating that its share price is 83% less volatile than the broader market. Comparatively, DRI Healthcare Trust has a beta of 0.472401, indicating that its share price is 53% less volatile than the broader market.

DRI Healthcare Trust has a net margin of 5.02% compared to Aurora Cannabis' net margin of -1.69%. DRI Healthcare Trust's return on equity of 2.06% beat Aurora Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
Aurora Cannabis-1.69% -1.15% -1.87%
DRI Healthcare Trust 5.02%2.06%4.22%

Summary

DRI Healthcare Trust beats Aurora Cannabis on 10 of the 15 factors compared between the two stocks.

How does Aurora Cannabis compare to Hydropothecary?

Hydropothecary (CVE:THCX) and Aurora Cannabis (TSE:ACB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

4.6% of Aurora Cannabis shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Hydropothecary has a net margin of 0.00% compared to Aurora Cannabis' net margin of -1.69%. Hydropothecary's return on equity of 0.00% beat Aurora Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
HydropothecaryN/A N/A N/A
Aurora Cannabis -1.69%-1.15%-1.87%

Aurora Cannabis has a consensus price target of C$9.25, indicating a potential upside of 119.71%. Given Aurora Cannabis' stronger consensus rating and higher probable upside, analysts clearly believe Aurora Cannabis is more favorable than Hydropothecary.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hydropothecary
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aurora Cannabis
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Aurora Cannabis had 2 more articles in the media than Hydropothecary. MarketBeat recorded 2 mentions for Aurora Cannabis and 0 mentions for Hydropothecary. Hydropothecary's average media sentiment score of 0.00 equaled Aurora Cannabis'average media sentiment score.

Company Overall Sentiment
Hydropothecary Neutral
Aurora Cannabis Neutral

Hydropothecary has higher earnings, but lower revenue than Aurora Cannabis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HydropothecaryN/AN/AN/AN/AN/A
Aurora CannabisC$373.12M0.67-C$44.16M-C$1.50N/A

Summary

Aurora Cannabis beats Hydropothecary on 6 of the 9 factors compared between the two stocks.

How does Aurora Cannabis compare to Tilray Brands?

Tilray Brands (TSE:TLRY) and Aurora Cannabis (TSE:ACB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

4.4% of Tilray Brands shares are held by institutional investors. Comparatively, 4.6% of Aurora Cannabis shares are held by institutional investors. 0.7% of Tilray Brands shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Tilray Brands has a beta of 3.007995, meaning that its stock price is 201% more volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.174133, meaning that its stock price is 83% less volatile than the broader market.

In the previous week, Tilray Brands had 1 more articles in the media than Aurora Cannabis. MarketBeat recorded 3 mentions for Tilray Brands and 2 mentions for Aurora Cannabis. Tilray Brands' average media sentiment score of 0.05 beat Aurora Cannabis' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tilray Brands
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aurora Cannabis
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Tilray Brands currently has a consensus target price of C$13.30, suggesting a potential upside of 89.19%. Aurora Cannabis has a consensus target price of C$9.25, suggesting a potential upside of 119.71%. Given Aurora Cannabis' stronger consensus rating and higher possible upside, analysts clearly believe Aurora Cannabis is more favorable than Tilray Brands.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tilray Brands
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Aurora Cannabis
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Aurora Cannabis has lower revenue, but higher earnings than Tilray Brands. Aurora Cannabis is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tilray BrandsC$858.28M0.98-C$183.24M-C$14.63N/A
Aurora CannabisC$373.12M0.67-C$44.16M-C$1.50N/A

Aurora Cannabis has a net margin of -1.69% compared to Tilray Brands' net margin of -158.75%. Aurora Cannabis' return on equity of -1.15% beat Tilray Brands' return on equity.

Company Net Margins Return on Equity Return on Assets
Tilray Brands-158.75% -88.06% -1.41%
Aurora Cannabis -1.69%-1.15%-1.87%

Summary

Tilray Brands and Aurora Cannabis tied by winning 8 of the 16 factors compared between the two stocks.

How does Aurora Cannabis compare to Knight Therapeutics?

Knight Therapeutics (TSE:GUD) and Aurora Cannabis (TSE:ACB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

In the previous week, Aurora Cannabis had 2 more articles in the media than Knight Therapeutics. MarketBeat recorded 2 mentions for Aurora Cannabis and 0 mentions for Knight Therapeutics. Knight Therapeutics' average media sentiment score of 0.00 equaled Aurora Cannabis'average media sentiment score.

Company Overall Sentiment
Knight Therapeutics Neutral
Aurora Cannabis Neutral

Knight Therapeutics has a net margin of 1.10% compared to Aurora Cannabis' net margin of -1.69%. Knight Therapeutics' return on equity of 0.73% beat Aurora Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
Knight Therapeutics1.10% 0.73% 0.51%
Aurora Cannabis -1.69%-1.15%-1.87%

Knight Therapeutics currently has a consensus target price of C$9.50, suggesting a potential upside of 1.60%. Aurora Cannabis has a consensus target price of C$9.25, suggesting a potential upside of 119.71%. Given Aurora Cannabis' higher probable upside, analysts plainly believe Aurora Cannabis is more favorable than Knight Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Aurora Cannabis
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Knight Therapeutics has a beta of -0.141784, suggesting that its share price is 114% less volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.174133, suggesting that its share price is 83% less volatile than the broader market.

23.9% of Knight Therapeutics shares are held by institutional investors. Comparatively, 4.6% of Aurora Cannabis shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Knight Therapeutics has higher revenue and earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Knight TherapeuticsC$510.45M1.80-C$30.73MC$0.06155.83
Aurora CannabisC$373.12M0.67-C$44.16M-C$1.50N/A

Summary

Knight Therapeutics beats Aurora Cannabis on 10 of the 14 factors compared between the two stocks.

How does Aurora Cannabis compare to Canopy Growth?

Canopy Growth (TSE:WEED) and Aurora Cannabis (TSE:ACB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Canopy Growth has a beta of 1.193568, indicating that its share price is 19% more volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.174133, indicating that its share price is 83% less volatile than the broader market.

4.3% of Canopy Growth shares are owned by institutional investors. Comparatively, 4.6% of Aurora Cannabis shares are owned by institutional investors. 0.2% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Canopy Growth presently has a consensus target price of C$1.97, suggesting a potential upside of 39.48%. Aurora Cannabis has a consensus target price of C$9.25, suggesting a potential upside of 119.71%. Given Aurora Cannabis' stronger consensus rating and higher possible upside, analysts plainly believe Aurora Cannabis is more favorable than Canopy Growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Canopy Growth
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Aurora Cannabis
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Aurora Cannabis has a net margin of -1.69% compared to Canopy Growth's net margin of -107.39%. Aurora Cannabis' return on equity of -1.15% beat Canopy Growth's return on equity.

Company Net Margins Return on Equity Return on Assets
Canopy Growth-107.39% -47.41% -3.83%
Aurora Cannabis -1.69%-1.15%-1.87%

Aurora Cannabis has higher revenue and earnings than Canopy Growth. Aurora Cannabis is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy GrowthC$278.39M2.14-C$1.05B-C$1.86N/A
Aurora CannabisC$373.12M0.67-C$44.16M-C$1.50N/A

In the previous week, Aurora Cannabis had 2 more articles in the media than Canopy Growth. MarketBeat recorded 2 mentions for Aurora Cannabis and 0 mentions for Canopy Growth. Canopy Growth's average media sentiment score of 0.71 beat Aurora Cannabis' score of 0.00 indicating that Canopy Growth is being referred to more favorably in the media.

Company Overall Sentiment
Canopy Growth Positive
Aurora Cannabis Neutral

Summary

Aurora Cannabis beats Canopy Growth on 10 of the 15 factors compared between the two stocks.

Get Aurora Cannabis News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACB vs. The Competition

Export
MetricAurora CannabisDrug Manufacturers IndustryMedical SectorTSE Exchange
Market CapC$248.93MC$2.37BC$6.49BC$12.01B
Dividend YieldN/A2.95%2.67%6.20%
P/E Ratio-2.814.9124.6536.68
Price / Sales0.671,644.84476.1210.13
Price / Cash1.2510.1843.0582.29
Price / Book0.4210.4810.454.38
Net Income-C$44.16MC$20.27BC$3.56BC$299.09M
7 Day Performance-14.43%-0.61%-2.43%-3.16%
1 Month Performance-10.43%6.33%0.23%-2.46%
1 Year Performance-48.97%18.19%21.35%39.86%

Aurora Cannabis Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACB
Aurora Cannabis
1.5733 of 5 stars		C$4.21
-8.3%		C$9.25
+119.7%		-43.5%C$248.93MC$373.12MN/A1,073
DHT.UN
DRI Healthcare Trust
2.9001 of 5 stars		C$18.50
+3.1%		C$25.50
+37.8%		+42.7%C$1.02BC$163.77MN/AN/A
THCX
Hydropothecary
N/AC$5.30
+6.6%		N/A+0.0%C$949.11MN/AN/AN/A
TLRY
Tilray Brands
1.521 of 5 stars		C$7.44
-2.1%		C$13.30
+78.8%		+21.4%C$889.85MC$858.28MN/A2,650
GUD
Knight Therapeutics
0.3394 of 5 stars		C$8.20
-0.5%		C$9.50
+15.9%		+54.5%C$805.07MC$510.45M136.67725

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:ACB) was last updated on 6/11/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel